- Jun 16, 2022
Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma
The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell ...
- Jan 19, 2022
FDA Approves Rare Pediatric Disease Designation for IMX-110 for Rhabdomyosarcoma
Officials with the FDA have approved a Rare Pediatric Disease Designation for IMX-110 for the treatment of pediatric patients with ...
- Jul 2, 2021
FDA Approves Rylaze as Alternative for Patients with ALL and Lymphoblastic Lymphoma
New FDA approval means that pediatric and adult patients with acute lymphoblastic leukemia (ALL) and lympoblastic lymphoma who are...
- Mar 26, 2021
Pediatric cancers have unique genetic vulnerabilities
Most cancer drugs that target specific genetic mutations are designed for adult cancers rather than those in children, partly because ...
- Mar 19, 2020
PD-1 Blocker Safe in Childhood Cancers. But Does It Work?
PD-1-directed immunotherapy was safe and tolerable in children and adolescents with previously treated cancers, though responses were...
- Nov 5, 2019
Chemotherapy sometimes set the stage for drug-resistant leukemia at relapse
An international collaboration has identified therapy-induced, drug-resistance mutations in children with acute lymphoblastic leukemia...
- Oct 15, 2019
The U.S. Is Running Out Of A Critical Childhood Cancer Drug And There Is No Suitable Replacement.
The U.S. is experiencing a critical shortage of a drug called vincristine, used to treat several types of childhood cancer including...
- Apr 16, 2019
Which chemotherapy drugs have the highest cardiotoxicity risk in pediatric cancer?
A recent study published in JAMA Oncology analyzed data generated from over 28,000 childhood cancer survivors and compared the lifetime...